Ascendis Pharma's Yorvipath Success and Strategic Pipeline Drive Buy Rating

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Ascendis Pharma, citing strong Yorvipath performance and strategic pipeline developments. The company's second-quarter revenues exceeded expectations, and the FDA approval for Skytrofa in adult growth hormone deficiency presents a long-term growth opportunity. Ahmad's revised price objective is $227, and TD Cowen also reiterated a Buy rating with the same price target.

Ascendis Pharma (NASDAQ: ASND) reported robust financial results for the second quarter of 2025, with total revenue reaching €158.0 million, a substantial 339% increase from €36.0 million in Q2 2024. The company's revenue growth was primarily driven by commercial products, with YORVIPATH® (palopegteriparatide) contributing €103.0 million and SKYTROFA® (lonapegsomatropin) adding €50.7 million. YORVIPATH® saw approximately 3,100 unique patient enrollments and over 1,500 prescribing healthcare providers in the U.S., while SKYTROFA® generated revenue from more than 30 countries outside the U.S. [1]

Key developments included the FDA's priority review of TransCon® CNP (navepegritide) for children with achondroplasia, with a PDUFA date of November 30, 2025, and SKYTROFA's U.S. approval for adult growth hormone deficiency treatment. Despite higher operating expenses, the company reported a significantly reduced net loss of €38.9 million (€0.64 per share), compared to €109.4 million (€1.91 per share) in Q2 2024. This 64.4% reduction in net loss demonstrates improving operational efficiency and commercial success. As of June 30, 2025, Ascendis maintained a solid cash position of €494 million. [1]

Analysts have responded positively to these results. Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Ascendis Pharma, citing strong Yorvipath performance and strategic pipeline developments. Ahmad's revised price objective is $227, and TD Cowen also reiterated a Buy rating with the same price target. [1]

The company's pipeline developments, particularly the FDA priority review of TransCon CNP and SKYTROFA's label expansion, position Ascendis for continued growth. The promising interim results from the COACH trial for combination therapy further strengthen their growth disorders franchise. Ascendis strengthens its rare endocrine disease portfolio with SKYTROFA adult approval and promising TransCon CNP data, addressing significant unmet needs. [1]

Ascendis Pharma's endocrine portfolio demonstrates remarkable clinical progress across multiple fronts. The FDA approval of SKYTROFA (lonapegsomatropin-tcgd) for adult growth hormone deficiency (GHD) represents a significant therapeutic advancement. The planned basket trial for additional indications including Idiopathic Short Stature, SHOX deficiency, Turner syndrome, and Small for Gestational Age will further expand SKYTROFA's clinical utility across the spectrum of growth disorders. The TransCon CNP (navepegritide) program for achondroplasia is approaching a critical milestone with FDA priority review and a November 30, 2025, PDUFA date. If approved, this would represent the first TransCon therapy for skeletal dysplasia, addressing the underlying pathophysiology of FGFR3-related growth disorders. [1]

The Week 26 interim data from the COACH trial investigating combination therapy of TransCon CNP with TransCon hGH in children with achondroplasia suggests potentially synergistic benefits from targeting complementary growth pathways simultaneously. The long-term TransCon PTH (YORVIPATH) data demonstrating normalization of calcium, phosphate, kidney function, bone turnover, and quality of life out to four years of treatment further highlights the company's innovative approach. The initiation of PaTHway60 to support titration up to 60 µg indicates the company is exploring optimal dosing paradigms to maximize therapeutic benefit. [1]

Collectively, these developments reflect a sophisticated therapeutic approach that focuses on physiological hormone replacement rather than symptomatic management of endocrine disorders. Ascendis Pharma's Q2 2025 results and pipeline developments position the company for continued growth and address significant unmet medical needs. [1]

References:
[1] https://www.stocktitan.net/news/ASND/ascendis-pharma-reports-second-quarter-2025-financial-uf8xwa0fvvkh.html